Natural Alternatives International Inc

Natural Alternatives International Inc(NAII)股票分析

$2.070

-0.039 (-1.90%)收盤時

Loading chart…
High
2.120
Open
2.110
VWAP
2.09
Vol
1.25K
Mkt Cap
38.26M
Low
2.070
Amount
2.62K
EV/EBITDA, TTM
0.00

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer's preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.

AI analysis of Natural Alternatives International Inc (NAII)

hold

Natural Alternatives International Inc is not a good buy right now due to ongoing financial losses and declining performance metrics. The current price is $2.16, and the company reported a net loss of $4.3 million for Q3 2026, translating to a diluted loss of $0.72 per share. Although there was a 23% increase in net sales compared to the previous year, the overall financial health remains concerning, particularly with a forward P/E of 13.61 indicating potential overvaluation given the losses.

估值指標

The current forward P/E ratio for Natural Alternatives International Inc (NAII) is 13.61, compared to its 5-year average forward P/E of 2.00.

Forward P/E

Strongly Overvalued
5Y Average P/E
2.00
Current P/E
13.61
高估
7.20
低估
-3.20

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for NAII

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NAII

$3.15

情境價格

B

Base

Base · 50%NAII

$3.11

情境價格

B

Bear

Bear · 25%NAII

$2.93

情境價格

NAII FAQ — answered by Alphio AI

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer's preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Natural Alternatives International Inc is not a good buy right now due to ongoing financial losses and declining performance metrics. The current price is $2.16, and the company reported a net loss of $4.3 million for Q3 2026, translating to a diluted loss of $0.72 per share. Although there was a 23% increase in net sales compared to the previous year, the overall financial health remains concerning, particularly with a forward P/E of 13.61 indicating potential overvaluation given the losses.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始